» Articles » PMID: 33414031

Can a COVID-19 Vaccine Live Up to Americans' Expectations? A Conjoint Analysis of How Vaccine Characteristics Influence Vaccination Intentions

Overview
Journal Soc Sci Med
Date 2021 Jan 8
PMID 33414031
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: A vaccine for the novel coronavirus (COVID-19) could prove critical in establishing herd immunity. While past work has documented the prevalence and correlates of vaccine refusal, I assess how a less explored topic -- properties of vaccines themselves (e.g., national origin, efficacy, risk of side effects) -- might influence vaccination intentions. This information can help public health officials preempt differential intentions to vaccinate, and inform health communication campaigns that encourage vaccine uptake.

Rationale: Previous research suggests that Americans should be more likely to intend to vaccinate if presented with a US-made vaccine that carries a low risk of minor side effects, is highly effective, is administered in just one dose, and has spent significant time in development.

Methods: I administered a conjoint experiment (N = 5940 trials) in a demographically representative survey (N = 990) of US adults to assess how variation in vaccine properties influence self-reported public vaccination intentions.

Results: I find that respondents prefer vaccines that are US-made, over 90% effective, and carry a less than 1% risk of minor side effects. This is potentially problematic, as some leading vaccine candidates are produced outside the US, and/or may be more likely to produce minor side effects than respondents would otherwise prefer. Worryingly, intended vaccine refusal rates exceed 30% for a vaccine meeting these optimal characteristics. Encouragingly, though, Americans show no clear preference for vaccines administered in one dose, or developed in under a year, and do not appear to draw a distinction between weakened viral vs. mRNA-based vaccines.

Conclusion: Americans' preferences for a novel coronavirus vaccine may be at odds with the vaccine that ultimately hits the market, posing both policy and health communication challenges for vaccination uptake.

Citing Articles

COVID-19 Vaccine Preferences in General Populations in Canada, Germany, the United Kingdom, and the United States: Discrete Choice Experiment.

Salisbury D, Lazarus J, Waite N, Lehmann C, Sri Bhashyam S, de la Cruz M JMIR Public Health Surveill. 2024; 10:e57242.

PMID: 39412841 PMC: 11525078. DOI: 10.2196/57242.


Which factors drive the choice of the French-speaking Quebec population towards a COVID-19 vaccination programme: A discrete-choice experiment.

Morillon G, Poder T Health Expect. 2024; 27(1):e13963.

PMID: 39102733 PMC: 10767688. DOI: 10.1111/hex.13963.


Factors influencing individual vaccine preferences for COVID-19 in the Sunyani Municipality, Ghana: An observational study using discrete choice experiment analysis.

Gyasi S, Kumi W, Kwofie C Health Sci Rep. 2024; 7(7):e2263.

PMID: 39050907 PMC: 11265991. DOI: 10.1002/hsr2.2263.


Acceptance and willingness to purchase a hypothetical COVID-19 vaccine in a region under Shariah law: A cross-sectional study in Aceh, Indonesia.

Rayhan M, Mudatsir M, Nurjannah N, Ichsan I, Amir-Behghadami M, Khader Y Narra J. 2024; 2(2):e85.

PMID: 38449698 PMC: 10914119. DOI: 10.52225/narra.v2i2.85.


Economic evaluation of vaccination against COVID-19: A systematic review.

Zeinab D, Shahin N, Fateme M, Saeed B Health Sci Rep. 2024; 7(2):e1871.

PMID: 38332928 PMC: 10850437. DOI: 10.1002/hsr2.1871.


References
1.
Lurie N, Saville M, Hatchett R, Halton J . Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020; 382(21):1969-1973. DOI: 10.1056/NEJMp2005630. View

2.
Britton T, Ball F, Trapman P . A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2. Science. 2020; 369(6505):846-849. PMC: 7331793. DOI: 10.1126/science.abc6810. View

3.
Folegatti P, Ewer K, Aley P, Angus B, Becker S, Belij-Rammerstorfer S . Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249):467-478. PMC: 7445431. DOI: 10.1016/S0140-6736(20)31604-4. View

4.
Nan X, Kim J . Predicting H1N1 vaccine uptake and H1N1-related health beliefs: the role of individual difference in consideration of future consequences. J Health Commun. 2013; 19(3):376-88. DOI: 10.1080/10810730.2013.821552. View

5.
Jackson L, Anderson E, Rouphael N, Roberts P, Makhene M, Coler R . An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020; 383(20):1920-1931. PMC: 7377258. DOI: 10.1056/NEJMoa2022483. View